Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10 ‐Day Dual Therapy

In this study,H. pylori patients (426) were enrolled and randomized into 3 groups: an EA14 group (20  mg of esomeprazole qid and 1000 mg of amoxicillin tid for 14 days), a VA14 group (20 mg of vonoprazan bid and 750 mg of amoxicillin qid for 14 days), and a VA10 group (20 mg of vonoprazan bid and 1000 mg of amoxicillin tid for 10 days). Key outcomes encompassed theH. pylori eradication rate, patient adverse effects, and compliance. In the EA14, VA14, and VA10 groups,H. pylori eradication rates were 89.4%, 90.1%, and 88.7% in intention-to-treat analysis, and 94.2%, 94.4%, and 94.6% in per-protocol analysis, respectively. Adverse events incidences were 14.8%, 12.7%, and 5.6%, while compliance rates were 88.7%, 90.9%, and 95.8%, respectively. Notably, the VA10 regimen demonstrated comparableH. pylori eradication rates, adverse effect incidences, and compliance levels to the EA14 and VA14 regimens.

Source: Clinical Pharmacology in Drug Development - January 11, 2024 Category: Drugs & Pharmacology Authors: Kunfeng Yan, Xiaorong Dai, Zhenxing Li, Weiwei Rong, Lei Chen, Xinxin Diao Tags: Original Article Source Type: research